Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001771348 | SCV002002566 | uncertain significance | not provided | 2021-02-11 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis supports that this missense variant has a deleterious effect on protein structure/function |
Labcorp Genetics |
RCV001771348 | SCV002280473 | uncertain significance | not provided | 2025-01-07 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 73 of the COL9A3 protein (p.Pro73Leu). This variant is present in population databases (rs768298010, gnomAD 0.006%). This variant has not been reported in the literature in individuals affected with COL9A3-related conditions. ClinVar contains an entry for this variant (Variation ID: 1314117). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt COL9A3 protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002503227 | SCV002786436 | uncertain significance | Epiphyseal dysplasia, multiple, 3; Intervertebral disc disorder | 2022-01-18 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004040281 | SCV004929799 | uncertain significance | Inborn genetic diseases | 2023-09-25 | criteria provided, single submitter | clinical testing | The c.218C>T (p.P73L) alteration is located in exon 4 (coding exon 4) of the COL9A3 gene. This alteration results from a C to T substitution at nucleotide position 218, causing the proline (P) at amino acid position 73 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |